Colinz Laboratories Ltd (BSE: 531210) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹18 Cr, it ranks #4,696 by market cap among the 6,137 Indian listed companies on FinBizNet, and #80 of 86 in Medicinal Chemicals and Botanical Products. At ₹67.50 (as of 25 Oct 2026), the share price is 23.2% below its 52-week high of ₹87.91 and 86.9% above its 52-week low of ₹36.11. The share price is up 60.9% over one year and down 14.2% over three months.
| Current Price | ₹67.50 |
|---|---|
| Market Cap | ₹18 Cr |
| BSE Code | 531210 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 34.3 |
| Return on Equity | 5.27% |
| Return on Assets | 1.28% |
| 52-Week Range | ₹36.11 – ₹87.91 |
| 1-Year Price Change | +60.9% |
| 3-Month Price Change | -14.2% |
| Beta (1Y) | 0.74 |
| Headquarters | Mumbai, Maharashtra |
| Website | www.colinz.com |
Colinz Laboratories Limited manufactures, markets, and trades in pharmaceutical formulations in India. The company offers pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, ointments, injectables, creams, syrups, suppositories, etc.; and specialized products for gynecology, cardiology, and gastroenterology, etc. Its allopathy products include oncology products, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim, pegylated liposome doxorubicin, etc.; antiritrovirals comprising lopinavir, indinavir, ritonavir, darunavir, zidovudine, lamivudin, and various combination therapy products; and products for other therapeutic areas, such as antibiotics, anti-fungals, anti-malarials, anti-virals, anti-manics, anti-convulsants, anti-migraines, anti-allergics, anthelmintics, anti-emetics, anti-inflammatory (NSAIDS), sedatives, cerebral activators, ulcer healing agents, laxatives, probiotics, dige
1. Pharmaceutical Formulation Business-This segment engages in manufacturing and marketing pharmaceutical formulations primarily for the gynecological sector in India. It also provides various therapeutic products and veterinary formulations; active pharmaceutical ingredients and intermediates; and provides product development and clinical research services, technical know how for formulations, and contract manufacturing services.
1. Manufacturing Pharmaceutical Formulations-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Colinz Laboratories Ltd | ₹18 Cr | 34.3 | 5.27% | — | +60.9% |
Listed by market capitalisation. Ratios are shown for context only.
Colinz Laboratories Ltd is trading at ₹67.50, with a market capitalisation of ₹18 Cr.
Colinz Laboratories Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Colinz Laboratories Ltd has a P/E of 34.3 and a return on equity of 5.27%.
Colinz Laboratories Ltd is listed on the BSE under the scrip code 531210.
Colinz Laboratories Ltd's share price is up 60.9% over one year and down 14.2% over three months. Its 52-week range is ₹36.11 to ₹87.91.
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.